B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
pmc: PMC8406170 , PMC8010725
B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
A novel SARS-CoV-2 variant termed B.1.526 was recently identified in New York City and has been found to be spreading at an alarming rate. The variant has mutations in its spike protein that might allow it to escape neutralization by vaccine-elicited antibodies and might cause monoclonal antibody therapy for COVID-19 to be less successful.
- New York University United States
Pfizer BNT162b2, COVID-19 Vaccines, SARS-CoV-2, Vaccination, Antibodies, Monoclonal, COVID-19, Observation, neutralization, spike protein, Antibodies, Viral, Moderna mRNA-1273, Microbiology, Antibodies, Neutralizing, QR1-502, Cell Line, HEK293 Cells, B.1.526, Spike Glycoprotein, Coronavirus, Humans, New York City
Pfizer BNT162b2, COVID-19 Vaccines, SARS-CoV-2, Vaccination, Antibodies, Monoclonal, COVID-19, Observation, neutralization, spike protein, Antibodies, Viral, Moderna mRNA-1273, Microbiology, Antibodies, Neutralizing, QR1-502, Cell Line, HEK293 Cells, B.1.526, Spike Glycoprotein, Coronavirus, Humans, New York City
5 Research products, page 1 of 1
- 2021IsAmongTopNSimilarDocuments
- 2020IsAmongTopNSimilarDocuments
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).65 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
